- Lun Oct 01, 2007 8:09 am
#53335
Hola amigos;
Aqui os dejo otro estudio donde indican que con 0,2 mg de finstaride al dia se obtienen niveles de inhibicion hormonal similares a 1 mg. (*)
Por otra parte en en enlace de la FDA, lo que me parece importante y no se comenta mucho es que el uso del finasteride altera la medida del PSA, antigeno especifico de la prostata, y es una cosa a tener muy en cuenta una vez que tengamos mas de 40 años. (**)
Un saludo y suerte
Armando
(*)
J Am Acad Dermatol. 1999 Oct;41(4):550-4.
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldstreicher J.
University of Oklahoma Health Sciences, Oklahoma City, USA.
BACKGROUND: Data suggest that androgenetic alopecia is a process dependent on dihydrotestosterone (DHT) and type 2 5alpha-reductase. Finasteride is a type 2 5alpha-reductase inhibitor that has been shown to slow further hair loss and improve hair growth in men with androgenetic alopecia. OBJECTIVE: We attempted to determine the effect of finasteride on scalp skin and serum androgens. METHODS: Men with androgenetic alopecia (N = 249) underwent scalp biopsies before and after receiving 0.01, 0.05, 0.2, 1, or 5 mg daily of finasteride or placebo for 42 days. RESULTS: Scalp skin DHT levels declined significantly by 13.0% with placebo and by 14.9%, 61.6%, 56. 5%, 64.1%, and 69.4% with 0.01, 0.05, 0.2, 1, and 5 mg doses of finasteride, respectively. Serum DHT levels declined significantly (P <.001) by 49.5%, 68.6%, 71.4%, and 72.2% in the 0.05, 0.2, 1, and 5 mg finasteride treatment groups, respectively. CONCLUSION: In this study, doses of finasteride as low as 0.2 mg per day maximally decreased both scalp skin and serum DHT levels. These data support the rationale used to conduct clinical trials in men with male pattern hair loss at doses of finasteride between 0.2 and 5 mg.
PMID: 10495374 [PubMed - indexed for MEDLINE]
(**)
Another effect is related to the PSA score which is often used as a possible test for the onset of prostate cancer. PROPECIA produces a decrease in the PSA score. Merck states that the average observed decease is 50%. Publishing average decreases is not sufficient without presenting some indication of the spread of such decreases. Such a decrease could mask the increase in score for a patient showing signs of cancer and might inhibit the request for a biopsy. It is feared that dermatologists might not transfer PROPECIA usage information to the patient's urologist and because of fluctuations, "doubling the PSA level", the recommended guideline, would be misleading